Xenetic Biosciences shares rise 10.89% premarket after extending DNase collaboration with Scripps Research, showing positive preclinical data for CAR-T combination.

Xenetic Biosciences surged 10.89% in premarket trading following the announcement of a 4-month extension of its research collaboration with Scripps Research and Dr. Alexey Stepanov to advance its DNase I (XBIO-015) program in combination with CAR-T cell therapies. The news highlighted preclinical data showing reduced tumor burden, metastatic lesions, and extended survival in cancer models, with systemic DNase I enhancing CAR-T efficacy by degrading neutrophil extracellular traps (NETs). The extension supports progression to mechanism-of-action and translational studies ahead of a Phase 1 clinical trial for pancreatic carcinoma and advanced solid tumors. The positive preclinical results and strategic collaboration reaffirm the company’s focus on DNase-based immuno-oncology platforms, aligning with the stock’s upward movement.